BRIEF published on 11/21/2025 at 11:25, 3 months 25 days ago Crossing of thresholds by Samsara BioCapital at INVENTIVA Voting Rights Capital Increase Threshold Crossing Inventiva Samsara BioCapital
PRESS RELEASE published on 11/13/2025 at 15:21, 4 months 3 days ago Inventiva announces pricing of upsized public offering of approximately $150M of American Depositary Shares
BRIEF published on 11/13/2025 at 08:45, 4 months 3 days ago Inventiva Announces Temporary Trading Halt on Euronext Paris Euronext Paris Nasdaq Trading Halt Inventiva ADS Offering
PRESS RELEASE published on 11/13/2025 at 08:40, 4 months 3 days ago Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris Inventiva temporarily halts trading of ordinary shares on Euronext Paris for public offering preparation, with expected resumption by end of day. Company focuses on MASH treatment research Euronext Paris Trading Halt Public Offering Inventiva MASH Treatment
BRIEF published on 10/14/2025 at 22:05, 5 months 1 day ago Inventiva Launches New ATM Program to Raise $100 Million Biopharmaceutical SEC Filing Inventiva Lanifibranor ATM Program
PRESS RELEASE published on 10/14/2025 at 22:00, 5 months 1 day ago Inventiva Announces the Implementation of a New ATM Program Inventiva implements new ATM program, files Registration Statement with the SEC for up to $100 million aggregate gross sales proceeds. Proceeds to fund research and development, working capital, and corporate purposes Biopharmaceutical SEC Registration Statement Inventiva ATM Program
BRIEF published on 10/07/2025 at 22:05, 5 months 8 days ago Inventiva at Liver Meeting 2025: Key Presentations on Lanifibranor Digital Pathology Inventiva MASH Lanifibranor Liver Meeting 2025
PRESS RELEASE published on 10/07/2025 at 22:00, 5 months 8 days ago Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025 Inventiva to present multiple abstracts at AASLD The Liver Meeting® 2025 showcasing digital pathology data and therapeutic benefits of lanifibranor in MASH treatment. Visit booth #745 for more Digital Pathology Inventiva MASH Lanifibranor AASLD The Liver Meeting
BRIEF published on 10/01/2025 at 08:35, 5 months 15 days ago Andrew Obenshain Appointed as CEO of Inventiva Leadership Transition Drug Development Inventiva MASH Treatment Andrew Obenshain
PRESS RELEASE published on 10/01/2025 at 08:30, 5 months 15 days ago Inventiva Appoints Andrew Obenshain as Chief Executive Officer Inventiva appoints Andrew Obenshain as Chief Executive Officer, succeeding Frédéric Cren, to lead company's growth and prepare for potential commercialization in the United States Chief Executive Officer Inventiva MASH Frédéric Cren Andrew Obenshain
Published on 03/16/2026 at 18:12, 1 hour 28 minutes ago Sekur Private Data Signs Distribution Agreement In Africa
Published on 03/16/2026 at 14:00, 5 hours 40 minutes ago Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression
Published on 03/16/2026 at 13:45, 5 hours 55 minutes ago iFabric Corp Provides Strong 2025 Revenue Estimate and 2026 Outlook
Published on 03/16/2026 at 13:30, 6 hours 10 minutes ago Ondas Completes Acquisition of Rotron Aerospace Ltd., Expanding Long-Range Propulsion Technologies for Advanced Unmanned Systems for Defense
Published on 03/16/2026 at 13:30, 6 hours 10 minutes ago An Asteroid Just Hit Earth - Where Did Everything Land? New Global Challenge Seeks Answers
Published on 03/16/2026 at 19:24, 15 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/16/2026 at 18:45, 55 minutes ago Cognizant Expands AI Infrastructure Capabilities with Launch of Cognizant AI Factory
Published on 03/16/2026 at 18:26, 1 hour 14 minutes ago M&G Credit Income Investment Trust plc: Net Asset Value(s)
Published on 03/16/2026 at 18:10, 1 hour 29 minutes ago BILENDI: BilendiUX expands internationally: Bringing Advanced Self-Service Recruitment to Local UX Teams
Published on 03/16/2026 at 18:00, 1 hour 40 minutes ago Disclosure of trading in own shares from 09/03/2026 to 13/03/2026
Published on 03/16/2026 at 17:58, 1 hour 42 minutes ago Aéroports de Paris S.A - February 2026 traffic figures
Published on 03/16/2026 at 17:56, 1 hour 43 minutes ago Reporting on share buyback transactions carried out between March 9 and March 13, 2026
Published on 03/16/2026 at 17:35, 2 hours 5 minutes ago Disclosure of transactions in own shares from March 9 to March 13, 2026
